Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

NCT04694781 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: LVGN6051
DRUG: Pembrolizumab

Sponsor

Lyvgen Biopharma Holdings Limited